Bio-Path stock: buy or sell?
July 15th, 2019
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development company in the United States.
Should I buy Bio-Path stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Following a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Bio-Path stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Bio-Path stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't detect any rating for BPTH stock for the last month.
Bio-Path stock analysis
After sliding for 4 days, Monday Bio-Path remained constant a tight 0.08%, closing at $12.90.
After sliding for 4 days, Monday Bio-Path remained stable a tight 0.08%, closing at $12.90. Since Jun 10th when BPTH stock price broke up the SMA200d line, it gained $0.38 (3.04%). In the last 39 days when SMA100d and SMA200d crossed up, BPTH price slipped $-0.07 per share (-0.54%).
Bio-Path stayed steady a neutral 0.08% this week. Late May BPTH plunged a spooky -14.22% in just one week. By mid June BPTH rocketed an outstanding 10.70% in just one week.
Having descending tops is not good news for investors in BPTH. Although it's only a warning signal, eyes should be on alert during next weeks to identify possible new risks. Loosing its previous bottom at would confirm the downtrend path. Since SMA20w and SMA40w crossed up late May, BPTH price slid a -16.93%. Since early March when BPTH stock price broke up the SMA40w line, it gained $5.18 (67.10%).
Bio-Path stock price history
Bio-Path stock went public on March 15th, 2010 with a price of $100.001. Since then, BPTH stock sliced a -87.10%, with a yearly average of -9.70%.
1: Adjusted price after possible price splits or reverse-splits.
Bio-Path stock historical price chart
BPTH stock reached 52-week highs on March at $73.52, and all-time highs 2014-01-03 with a price of 1050.
Bio-Path stock price targetNobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we have not detected any price forecast for Bio-Path stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter presenting its last earnings report on March, Bio-Path collapsed a dreadful -48.81%. As soon as we get its actual EPS from the earnings report, we will extend this review.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2017, Bio-Path annual revenues boosted an exceptional 184.62% to $0.04 M dollars from $0.01 marked in 2016. When comparing 2017 vs 2016, similarly, profit margin (that is, the net income divided by revenues) rocketed a 32,942.00% to -18,981.08%.
|2016||$0.01 M||-||$-6.75 M-51923.1%||-|
|2017||$0.04 M||184.62%||$-7.02 M-18981.1%||4.04%|
Quarterly financial resultsReported quarter earnings marked $-1.91 million with a profit margin of . Profit margin stayed stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing turnover to same quarter last year, Bio-Path sales marked a chilling correction and plunged a -100.00%. Looking back to recent quarterly results, Bio-Path posted 4 positive quarters in a row.
|2017-Q4||$0.04 M||-||$-2.17 M-5856.8%||-|
Bio-Path ownershipWhen you are planning to invest in a company, it's always worth to overview its ownership structure.
Bio-Path shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 5.62% of all shares.
In case of Bio-Path stock, 28.47% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for BPTH stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related companies:
|Market cap||$146.3 M|
|Total shares||11.3 M|
|Float shares||2.2 M|
|- Institutional holdings (%)||28.5%|
|- Insider holdings (%)||5.6%|
|Shares in short selling||0.0%|
|Monday, July 15th, 2019|
|Day range||$12.65 - $13.13|
|Average true range||$0.89|
|50d mov avg||$14.35|
|100d mov avg||$16.05|
|200d mov avg||$11.38|
Bio-Path performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. In the following table, we compare Bio-Path performance to :